In recent years, targeted therapy has played an increasingly important role in the comprehensive treatment of breast cancer due to its high degree of specificity, selectivity, affinity and non-cytotoxicity. Paposini is one of them. Paposini is an oral medicine. It only needs to be taken once a day, 125mg at a time, for 3 consecutive weeks and 1 week of rest, regardless of location restrictions. Clinically, Paposinib can double the non-progressive survival of breast cancer compared to letrozole, which is a new hope for breast cancer patients, and a progressive breakthrough in the efficacy has been achieved.
Common name: Pipercillin
English name: Ibrance (palbociclib Capsules)
Chinese name; Pipersilipabosinib Capsules
Applicable conditions: Piperacillin capsules are used to treat hormone receptor-positive and human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. It should be used in combination with aromatase inhibitors as an initial endocrine therapy for postmenopausal women.
Drug specifications: (1) 75 mg (2) 100 mg (3) 200 mg
Recommended dose: The recommended dose of piperacillin is once a day for 21 consecutive days, followed by 7 days of discontinuation (3/1 dosing regimen) and 28 days as the treatment cycle. Unless the patient no longer has clinical benefit or has unacceptable toxicity, treatment should continue. When combined with letrozole, the recommended dose of letrozole is 2.5mg, which is taken orally once a day and continuously throughout the 28-day treatment cycle. For details, please refer to the manual of the letrozole standard. The method of administration is oral. It should be taken with food, preferably with food, to ensure consistent exposure to pipercillin.
Precautions：Palbociclib should not be taken with grapefruit or grapefruit juice. Palbociclib capsules should be swallowed whole (do not chew, crush, or open the capsule before swallowing). Do not take the medication if the capsule is damaged, broken, or incomplete. Patients should be encouraged to take the medication at approximately the same time each day. If a patient vomits or misses a dose, do not take another dose on the same day. The next dose should be taken as usual. Do not receive any immunizations or vaccines while taking piperacillin without your doctor's consent. Be sure to tell your doctor about any other medications you are taking (including prescription drugs, over-the-counter drugs, vitamins, herbal remedies, etc.). Do not take palbociclib unless explicitly permitted by your doctor. Pregnant women should not take this medication, and good contraception should be used during treatment. When premenopausal/non-menopausal women receive combined treatment with palbociclib and aromatase inhibitors, they must undergo oophorectomy or use luteinizing hormone-releasing hormone agonists to suppress ovarian function. Patients with severe internal organ disease are not permitted to take this medication. Patients with liver or kidney damage or insufficiency should not take this medication.
The female breast is composed of skin, fibrous tissue, breast glands and fat. Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast glands. 99% of breast cancer occurs in women, while men account for only 1%, so breast cancer is also known as the ”red-faced killer“ and ”pink killer." The global incidence of breast cancer has been on the rise since the late 1970s and has become a major public health issue in the current society.
The appearance of Paposini has brought hope to all breast cancer patients. It not only inhibits the growth of breast cancer physically, but also psychologically gives breast cancer patients great comfort. Paposini is an experimental, oral, targeted preparation that can selectively inhibit cyclin-dependent kinases 4 and 6 (CDK4/6), restore cell cycle control, block tumor cell proliferation, and thereby inhibit the growth of G1 ER+ breast cancer cells. Paposini can be said to be a killer who specializes in killing “red-faced killers”! Its curative effect can be said to be immediate and well-deserved.
Palbociclib therapy is playing an increasingly important role in the comprehensive treatment of breast cancer due to its high specificity, selectivity, affinity, and non-cytotoxicity. Palbociclib is one of the most recently studied and important experimental drugs developed by Pfizer. It is an orally administered targeted drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), restoring cell cycle regulation and preventing tumor cell proliferation. In first- and second-line treatments using letrozole and fulvestrant, the combination of palbociclib and letrozole resulted in progression-free survival several times higher than with letrozole or fulvestrant alone. Phase III clinical trial results showed that, compared to letrozole alone, palbociclib combined with letrozole for the treatment of advanced postmenopausal hormone receptor-positive, HER2-negative breast cancer patients doubled progression-free survival (24.8 months vs. 10.3 months); and compared to fulvestrant alone, progression-free survival was doubled (9.2 months vs. 3.8 months).
